Literature DB >> 21807788

Overview of the patient perspective at OMERACT 10--conceptualizing methods for developing patient-reported outcomes.

John R Kirwan1, Peter S Tugwell.   

Abstract

This overview draws out the main conclusions from the 4 workshops focused on incorporating the patient perspective into outcome assessment at the 10th Outcome Measures in Rheumatology (OMERACT 10) conference. They raised methodological issues about the choice of outcome domains to include in clinical trials, the development or choice of instruments to measure these domains, and the way these instruments might capture the impact of a disease and its treatment. The need to develop a more rigorous conceptual model of quantifying the way conditions affect health, and the need to ensure patients are directly involved in the decisions about domains and instruments, emerged clearly. The OMERACT participants voted to develop guidelines for domain and instrument selection, and conceptual and experimental work will be brought forward to revise and upgrade the OMERACT Filter.

Entities:  

Mesh:

Year:  2011        PMID: 21807788     DOI: 10.3899/jrheum.110388

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.

Authors:  John D Pauling; Robyn T Domsic; Lesley A Saketkoo; Celia Almeida; Jane Withey; Hilary Jay; Tracy M Frech; Francesca Ingegnoli; Emma Dures; Joanna Robson; Neil J McHugh; Ariane L Herrick; Marco Matucci-Cerinic; Dinesh Khanna; Sarah Hewlett
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-08-16       Impact factor: 4.794

2.  A comparison of telephone and paper self-completed questionnaires of main patient-related outcome measures in patients with ankylosing spondylitis and psoriatic arthritis.

Authors:  Rafael Ariza-Ariza; Blanca Hernández-Cruz; Victoria Navarro-Compán; Christian Leyva Pardo; Xavier Juanola; Federico Navarro-Sarabia
Journal:  Rheumatol Int       Date:  2013-06-21       Impact factor: 2.631

3.  Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group.

Authors:  Jennifer Petkovic; Jennifer L Barton; Caroline Flurey; Niti Goel; Christie M Bartels; Cheryl Barnabe; Maarten P T de Wit; Anne Lyddiatt; Diane Lacaille; Vivian Welch; Annelies Boonen; Beverley Shea; Robin Christensen; Lara J Maxwell; Willemina Campbell; Janet Jull; Karine Toupin-April; Jasvinder A Singh; Charles H Goldsmith; Antoine G Sreih; Christoph Pohl; Catherine Hofstetter; Dorcas E Beaton; Rachelle Buchbinder; Francis Guillemin; Peter S Tugwell
Journal:  J Rheumatol       Date:  2017-02-15       Impact factor: 4.666

4.  Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD).

Authors:  Shikha Mittoo; Sid Frankel; Daphne LeSage; Vibeke Strand; Ami A Shah; Lisa Christopher-Stine; Sonye Danoff; Laura K Hummers; Jeffery J Swigris; Dörte Huscher; Angela M Christensen; Sophia L Cenac; Jen K Erbil; Sancia Ferguson; Ignacio Garcia-Valladares; Harmanjot K Grewal; Ana-Maria Orbai; Katherine Clegg Smith; Maithy Tran; Clifton O Bingham; Flavia V Castelino; Aryeh Fischer; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015-06

5.  Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Authors:  Vibeke Strand; Mark Kosinski; Chieh-I Chen; George Joseph; Regina Rendas-Baum; Neil M H Graham; Hubert van Hoogstraten; Martha Bayliss; Chunpeng Fan; Tom Huizinga; Mark C Genovese
Journal:  Arthritis Res Ther       Date:  2016-09-06       Impact factor: 5.156

Review 6.  How Can We Improve Disease Education in People with Gout?

Authors:  Theodore R Fields; Adena Batterman
Journal:  Curr Rheumatol Rep       Date:  2018-03-08       Impact factor: 4.592

7.  Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Authors:  Vibeke Strand; Matthew Reaney; Chieh-I Chen; Clare W J Proudfoot; Sophie Guillonneau; Deborah Bauer; Erin Mangan; Neil M H Graham; Hubert van Hoogstraten; Yong Lin; César Pacheco-Tena; Roy Fleischmann
Journal:  RMD Open       Date:  2017-03-07

8.  Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?

Authors:  Aprajita Jagpal; Ronan O'Beirne; Melanie S Morris; Bernadette Johnson; James Willig; Huifeng Yun; Andrea L Cherrington; Liana Fraenkel; Jeffrey R Curtis; Monika M Safford; Iris Navarro-Millán
Journal:  BMC Rheumatol       Date:  2019-09-05

9.  Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.

Authors:  Vibeke Strand; Janet Pope; Namita Tundia; Alan Friedman; Heidi S Camp; Aileen Pangan; Arijit Ganguli; Mahesh Fuldeore; Debbie Goldschmidt; Michael Schiff
Journal:  Arthritis Res Ther       Date:  2019-12-09       Impact factor: 5.156

10.  Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial.

Authors:  Vibeke Strand; Eun Bong Lee; Roy Fleischmann; Rieke E Alten; Tamas Koncz; Samuel H Zwillich; David Gruben; Bethanie Wilkinson; Sriram Krishnaswami; Gene Wallenstein
Journal:  RMD Open       Date:  2016-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.